

Acquisition Brief — xgenetics.ai



Acquisition Brief — Xgenetics.ai

Domain name / Asset offered: xgenetics.ai (single asset; no other extensions included)

Purpose: acquisition of a strategic digital banner to host and steer an AI-enabled genetics programme

(R&D, data, safety/ethics, clinical & industrial partnerships).

Contacts

Email • contact@xgenetics.ai

Website • <https://www.xgenetics.ai>

LinkedIn • <https://www.linkedin.com/company/xgeneticsai>

This document — for whom, and why

Decision brief for CEO / COO / CFO / CTO / Chief Medical Officer / Regulatory & Ethics

(digital health, rare diseases, biotech, pharma, hospitals, data platforms).

Thesis: owning the language of the category creates operational and reputational advantage.

XGENETICS.AI is a neutral banner to align R&D, Data, Clinical, Quality/Regulatory, Safety & Ethics around:

- rare genetic diseases,
 - undiagnosed conditions (“X diseases”, SWAN),
 - AI programmes applied to human genetics.
-

1. One-page decision

What it is.

A strategic (.ai) asset to name, structure and make visible a “Genetics & AI” programme:

- **institutional public portal,**
- **internal framework (data / model governance),**
- **anchor point for the ecosystem (patients, clinicians, partners, investors).**

What it changes.

- **Single entry point → clear narrative for patients, authorities, partners.**
- **Readable programme → better coordination between R&D, IT/Data, clinical, legal, ethics.**
- **Reduced time-to-trust → the programme brand becomes a reference in an anxiety-prone area (AI + genetics).**

What you can deploy immediately.

- **“Genetics & AI — Readiness & Rollout” programme: vision, priority use cases, roadmap.**
- **Resource hub: best practices (data quality, model robustness, explainability).**
- **Ethics & communication framework: validated messages for patients, regulators, media, investors.**

2) Market context & 2025-2032 window

- **Acceleration of large-scale sequencing and analysis.**
- **Growing use of AI for variant interpretation and patient stratification.**
- **Increasing regulatory pressure: data protection, algorithm transparency, informed consent.**
- **Strong societal expectations around rare diseases and undiagnosed conditions.**

In this context, a genetics & AI programme that is poorly named or fragmented becomes:

- harder to explain,
- more exposed in the media,
- riskier with authorities and ethics committees.

XGENETICS.AI offers a durable programme banner for this new generation of initiatives.

3) The problem to solve (Board view)

Without a clear banner:

- Multiple internal “AI projects” with no overall coherence.
- Difficulty telling a simple story to patients, clinicians, payers, investors.
- Communication risk: AI + genetics is sensitive; misunderstandings are costly.
- Fragmented data & model governance → higher risk on confidentiality, bias, compliance.

Board-level question:

“How do we make this programme readable, governable and defensible in front of patients, authorities and the media for the next 10 years?”

4) What XGENETICS.AI enables

4.1. Neutral, extensible programme name

- Suitable for a foundation, hospital, private group, biopharma, data platform.
- Can cover research, clinical pilots, and patient-facing digital services.
- Does not compete with existing brands: it sits above them as a programme banner.

4.2. Data & AI governance framework

- Public page: principles, charters, committees, transparency reports.
- Internal layer: shared reference for collecting, storing, accessing and using sensitive data.

4.3. Strong signal to the ecosystem

- Clear message to expert centres, patient organisations, industrial partners: “We run a structured AI & genetics programme and here is where to find it.”

4.4. Reputational & ESG asset

- **Traceability of commitments (reports, indicators, publications).**
 - **Better readability for investors, analysts and regulators on risk and impact management.**
-

5) Priority use cases (12–36 months)

Examples:

- **Hospital / hospital network: central programme for rare diseases & SWAN patients.**
 - **Biopharma / biotech: banner for a portfolio of clinical trials where AI interacts with genetic data.**
 - **Digital health platform: trust hub explaining how AI is used on very sensitive data.**
 - **National / regional initiative: framework to coordinate several centres or patient registries.**
-

6) Governance & internal integration

Possible options:

- **Domain hosted at corporate level (Communications / Corporate Affairs).**
 - **Joint ownership by Medical leadership & Data/AI leadership, with a dedicated ethics committee.**
 - **Governance documented on xgenetics.ai:**
 - **committee composition,**
 - **rules for selecting use cases,**
 - **principles for model updates and withdrawals.**
-

7) Integration with existing brands & products

- **XGENETICS.AI is not a product brand, but a programme umbrella.**
 - **Product, trial, platform or app names remain unchanged; they cascade under the banner.**
 - **Controlled co-branding: “XGENETICS.AI programme — [Study / platform name]”.**
 - **Reduced risk of proliferating slogans or brands that are hard to maintain over time.**
-

8) Scope of transfer & options

- **Asset transferred: xgenetics.ai only.**
 - **“Bare” domain transfer: no transfer of data, software, or intellectual property on models/algorithms.**
 - **Option to discuss, at buyer’s request, the addition of one extra digital asset to reinforce the programme (to be defined during negotiation).**
 - **No other name is mentioned in this document; at most one additional asset could be considered, outside the scope of this brief.**
-

9) Acquisition process (Legal/Finance)

- **Object of transfer: xgenetics.ai only.**
- **Standard process:**
 - **agreement on price and terms,**
 - **domain transfer agreement,**
 - **optional escrow service,**
 - **fast domain transfer,**
 - **invoice issued (French / European structure).**

- **Possible structures:**
 - **lump-sum payment,**
 - **staged payment (e.g. 40-30-30, to be discussed),**
 - **potential bundle with other digital assets, if relevant for the buyer.**
- **NDA and limited audit (targeted due diligence on the asset) available if needed.**

Legal notice:

- **Descriptive name, no affiliation with any existing entity;**
- **No medical claims: the name does not replace regulatory approvals, clinical validation or marketing authorisations.**

10) Contacts

Email • contact@xgenetics.ai

Website • <https://www.xgenetics.ai>

LinkedIn • <https://www.linkedin.com/company/xgeneticsai>